•If CTX ≤ pre-menopausal mean (i.e. treatment target) at baseline, statistically significant increases in CTX seen at 4 and 12 months
•If CTX > pre-menopausal mean at baseline, no significant change at 4 months, significant by 12 months •No significant difference between Alendronic acid and Risedronate seen (data not shown)
Monitoring outcomes using population data (figure 4):
•Baseline CTX not suppressed to premenopausal mean level after 5 yrs of BP use in 32% patients
•Where CTX suppressed at baseline:
-At 4 months 28% had significant rise in CTX that was also above mean level (?consider re-start)
-At 12 months this had risen to 53%; 47% CTX still suppressed at this stage
